Methods and Compositions related to HIF-1 alpha

(canceled)

(canceled)

A method of treating metastasis in a subject with cancer in vivo, comprising:

• administering to a subject in need thereof an effective amount of an inhibitor of lysyl oxidase activity, thereby inhibiting metastasis, in the subject treated.

14-36. (canceled)

A method of treating a subject with cancer, comprising administering to the subject an effective amount of an inhibitor of a component of the Myc pathway, along with antiangiogenesis treatment.

The method of claim 38, wherein the wherein the component is Sp1.

40-48. (canceled)

A method of staging tumor growth or metastasis in a subject, comprising:

• assessing HIF-1α levels in a tumor of the subject, whereby a change in HIF-1α level in the tumor in comparison with a reference sample indicates the presence of metastatic tumor growth.

The method of claim 50, wherein an increase in HIF-1α level in the tumor in comparison with a reference sample indicates the presence or increase of metastatic tumor growth.

(canceled)

The method of claim 53, wherein the level of HIF-1α protein in the tumor is measured with an antibody to HIF-1α.

55-59. (canceled)

A method for increasing the expression in a target cell of a hypoxia-inducible gene, said method comprising the steps of:

• (a) introducing into said cell an expression vector comprising a nucleic acid molecule encoding a polypeptide comprising PAS-B of a hypoxia inducible factor, wherein the PAS-B comprises at least one mutation which differs from naturally occurring PAS-B of a hypoxia inducible factor;
• and (b) allowing expression of said protein encoded by said expression vector.

61-71. (canceled)

A method for treating an HIF-1-mediated disorder in a subject comprising administering an effective amount of an HIF-1α PAS-B inhibitor or a mutant PAS-B.

The method of claim 73, wherein the HIF-1α PAS-B inhibitor or a mutant PAS-B reduces the level of expression of HIF-1α.

(canceled)

76-94. (canceled)